The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
ICE CREAM: Irinotecan cetuximab evaluation and the cetuximab response evaluation among patients with G13D mutation.
Eva Segelov
No relevant relationships to disclose
Kate Wilson
No relevant relationships to disclose
Val Gebski
No relevant relationships to disclose
Paul Michael Waring
No relevant relationships to disclose
Josep Tabernero
No relevant relationships to disclose
Harpreet Wasan
Honoraria - Merck
Research Funding - Merck
Other Remuneration - Merck
Fortunato Ciardiello
No relevant relationships to disclose
Jayesh Desai
No relevant relationships to disclose
Craig Underhill
Research Funding - Merck
Christos Stelios Karapetis
Consultant or Advisory Role - Merck Serono
Honoraria - Merck Serono
Mustafa Khasraw
No relevant relationships to disclose
Louise M. Nott
No relevant relationships to disclose
Warren Lance Joubert
No relevant relationships to disclose
Nick Pavlakis
No relevant relationships to disclose
Guy Van Hazel
No relevant relationships to disclose
Lorraine A. Chantrill
Consultant or Advisory Role - Merck Serono (U)
Timothy Jay Price
No relevant relationships to disclose
Michael Jefford
No relevant relationships to disclose
Andrew Mark Haydon
No relevant relationships to disclose
Jeremy David Shapiro
No relevant relationships to disclose